文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Baricitinib for COVID-19: a suitable treatment? - Authors' reply.

作者信息

Richardson Peter J, Corbellino Mario, Stebbing Justin

机构信息

Benevolent AI, London, UK.

III Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy.

出版信息

Lancet Infect Dis. 2020 Sep;20(9):1013-1014. doi: 10.1016/S1473-3099(20)30270-X. Epub 2020 Apr 3.

DOI:10.1016/S1473-3099(20)30270-X
PMID:32251639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7271155/
Abstract
摘要

相似文献

[1]
Baricitinib for COVID-19: a suitable treatment? - Authors' reply.

Lancet Infect Dis. 2020-9

[2]
Baricitinib for COVID-19: a suitable treatment?

Lancet Infect Dis. 2020-9

[3]
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.

J Infect. 2020-6-24

[4]
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?

Expert Opin Drug Saf. 2020-10

[5]
Predictors of arrhythmia other than QT interval prolongation and the use of β-blocker therapy in the coronavirus disease 2019 pandemic. Authors' reply.

Kardiol Pol. 2020-8-25

[6]
COVID-19: combining antiviral and anti-inflammatory treatments.

Lancet Infect Dis. 2020-4

[7]
Can artificial intelligence identify effective COVID-19 therapies?

EMBO Mol Med. 2020-7-7

[8]
[Baricitinib in the treatment of SARS-CoV-2 infection].

Rev Esp Quimioter. 2020-8

[9]
Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend? Authors' reply.

Pol Arch Intern Med. 2020-10-29

[10]
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.

EMBO Mol Med. 2020-6-24

引用本文的文献

[1]
Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches.

Drug Des Devel Ther. 2024

[2]
Polypharmacology guided drug repositioning approach for SARS-CoV2.

PLoS One. 2023

[3]
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.

Genes Dis. 2023-7

[4]
Drug development process and COVID-19 pandemic: Flourishing era of outsourcing.

Indian J Pharmacol. 2022

[5]
Abnormal Airway Mucus Secretion Induced by Virus Infection.

Front Immunol. 2021

[6]
Inflammatory Mechanism and Clinical Implication of Asthma in COVID-19.

Clin Med Insights Circ Respir Pulm Med. 2021-9-24

[7]
Recent advances and developments in COVID-19 in the context of allergic diseases.

Clin Transl Allergy. 2021-9

[8]
Repurposing Vandetanib plus Everolimus for the Treatment of -Mutant Diffuse Intrinsic Pontine Glioma.

Cancer Discov. 2022-2

[9]
Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges.

Front Microbiol. 2021-8-25

[10]
How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility.

Front Immunol. 2021

本文引用的文献

[1]
COVID-19: consider cytokine storm syndromes and immunosuppression.

Lancet. 2020-3-28

[2]
COVID-19: combining antiviral and anti-inflammatory treatments.

Lancet Infect Dis. 2020-4

[3]
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.

Lancet. 2020-2-15

[4]
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.

J Clin Invest. 2019-7-29

[5]
Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome.

J Virol. 2007-8

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索